Brief: Bavarian Nordic Gets Smallpox/Mpox Vaccine Supply Contract
09/06/2026 11:56
BRIEF-Bavarian Nordic Gets Smallpox/Mpox Vaccine Supply Contract June 9 (Reuters) - Bavarian Nordic A/S BAVA.CO:
BAVARIAN NORDIC SECURES ADDITIONAL GOVERNMENT CONTRACT FOR THE SUPPLY OF SMALLPOX/MPOX VACCINE
CONTRACT VALUED AT OVER DKK 700 MILLION
TO SUPPLY ITS MVA-BN SMALLPOX/MPOX VACCINE TO AN UNDISCLOSED COUNTRY
OVERALL GUIDANCE FOR 2026 REMAINS UNCHANGED AT REVENUE OF DKK 5,500-5,700 MILLION AND AN EBITDA MARGIN OF ABOUT 28%
FOR FULL YEAR 2026, COMPANY STILL ANTICIPATES REVENUE FROM PUBLIC PREPAREDNESS TO REACH DKK 2,300-2,500 MILLION
Source text: ID:nGNE1rMr27
Further company coverage: BAVA.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Bavarian Nordic A/S
See all newsBrief: Bavarian Nordic Gets Smallpox/Mpox Vaccine Supply Contract
Brief: Bavarian Nordic Secures Additional Government Contract For The Supply Of Smallpox/Mpox Vaccine
Brief: Bavarian Nordic Launches Final Tranche Of Buy-Back Program
Bavarian Nordic falls as high costs, lower vaccine sales hit Q1 results
Bavarian Nordic Q1 revenue falls as Public Preparedness unit sales decline